TAP Using Dexmedetomidine and Ropivacaine for Cesarean Section Analgesia

Summary

To evaluate the effect of dexmedetomidine as an adjuvant of ropivacaine in the TAP block on cesarean section parturients under multimodal analgesia, optimize the multimodal analgesia program for cesarean section, and guide perioperative analgesia managemen。This is a single center, double-blind, randomized clinical trial.

Timeline

Start

2023-05-31

Primary completion

2023-09-28

Completion

2023-09-30

Outcome

Missed primary endpoint

paper Opioid consumption (morphine equivalents, MEQ) in the postoperative 48 h showed no significant difference in Group R and Group RD (median, 12.54 mg MEQ vs. 13.86 mg MEQ), p = 0.853. PMID 41578187 ↗

paper Dexmedetomidine as adjuvant of posterior bilateral TAPB in parturients under multimodal analgesia did not decrease the consumption of opioids PMID 41578187 ↗

Publications

• Wang Y, Wang L, Wang Y, Mu X, Zhao B, Liu T, Nie H. Dexmedetomidine as adjuvant of transversus abdominal plane block for cesarean delivery under multimodal analgesia: a randomized clinical trial. BMC Anesthesiol. 2026 Jan 23;26(1):147. doi: 10.1186/s12871-026-03642-0.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dexmedetomidine	Other / unclassified	0.5 ug/kg	Other

Indications

No indication recorded.